A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
Status:
Completed
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if treatment with a medication called Nucala®
(mepolizumab), given along with standard asthma care, makes children less likely to have
asthma attacks.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
GlaxoSmithKline Inner-City Asthma Consortium Rho Federal Systems Division, Inc.